Trial Profile
A randomised, double-blind, double-dummy, parallel-group, placebo-controlled study comparing correlates of brain functional activation before and after treatment with placebo, active comparator paroxetine and GW679769 in subjects with Major Depressive Disorder.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Aug 2023
Price :
$35
*
At a glance
- Drugs Casopitant (Primary) ; Paroxetine
- Indications Major depressive disorder
- Focus Biomarker; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 15 Jun 2011 New trial record